May 24, 2024 12:53 PM EDT
Pharma
FDA+

FDA de­nies Ipsen's cit­i­zen pe­ti­tion for block­buster drug So­mat­u­line

Katherine Lewin

News Reporter

US drug reg­u­la­tors have turned down Ipsen’s ef­fort to slow down gener­ic com­pe­ti­tion for its block­buster drug So­mat­u­line De­pot, which is used to slow the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

A service from the Financial Times